The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Comparing the thromboembolic risk with KRd versus VRd in newly diagnosed myeloma
Bruno Costa, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses his work evaluating the risk of thromboembolic events in patients with newly diagnosed multiple myeloma (MM), emphasizing differences between KRd (carfilzomib, lenalidomide, and dexamethasone) and VRd (bortezomib, lenalidomide, and dexamethasone) treatment regimens. This meta-analysis of six studies involving 2,300 patients found a significantly lower rate of venous thromboembolism (VTE) events in the VRd group compared to the KRd group despite minimal differences in arterial thrombotic events between the regimens. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
